(Fox News) – An independent nonprofit organization that evaluates clinical and cost effectiveness of new medicines said announced prices for a just-approved class of potent cholesterol lowering drugs were far too high, according to a draft report released on Tuesday. The Boston-based Institute for Clinical and Economic Review (ICER) said its analyses indicated “that the […]
